Efekt komplexu 2-Aticyto a D-ribózy na bolest a klinický průběh u pacientů s fibromyalgií
Efekt 2-Aticyto komplexu a D-ribózy na bolest, symptomy a klinický průběh u pacientů se syndromem fibromyalgie
This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Fibromyalgia syndrome is a chronic condition associated with widespread pain, fatigue, sleep disturbance, and reduced quality of life. Although standard pharmacologic treatments such as pregabalin and duloxetine are commonly used, symptom control may remain incomplete in many patients. This study was designed to investigate whether adding a supplement containing 2-Aticyto Complex and D-ribose to ongoing standard treatment can improve clinical outcomes in adults with fibromyalgia syndrome.
This is a multicenter, randomized, double-blind, placebo-controlled clinical study. Adults aged 18 to 65 years with fibromyalgia syndrome, diagnosed according to the ACR 2016 criteria, followed for at least 1 year, and receiving pregabalin and/or duloxetine treatment for at least 3 months will be eligible for participation. Major exclusion criteria include rheumatologic disease, renal failure, hepatic failure, cardiovascular disease, diabetes or hypoglycemia, neurologic disease, use of other supplements, allergy to study product ingredients, inability to complete study procedures, or refusal to participate.
After eligibility assessment and informed consent, participants will be randomly assigned to one of two study groups: placebo plus ongoing standard treatment or FibroThol plus ongoing standard treatment. The study treatment will be administered orally at a dose of 15 mL three times daily for 4 weeks. Study visits and assessments will be performed at baseline, week 2, and week 4.
Outcome measures will include pain intensity, neuropathic pain, fibromyalgia-related functional status, fatigue, sleep quality, anxiety, and depression, assessed using validated clinical scales. Safety will be evaluated through adverse event monitoring during the study period.
A total of 200 participants will be enrolled, with 100 participants assigned to the FibroThol group and 100 participants assigned to the placebo group. The primary objective is to determine whether the addition of 2-Aticyto Complex and D-ribose to standard treatment provides additional benefit in reducing pain and improving symptoms and overall clinical course in patients with fibromyalgia syndrome.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Kubra Neslihan Kurt Oktay, MD
- Telefonní číslo: +905352916609
- E-mail: drneslihankurt@gmail.com
Studijní místa
-
-
-
Istanbul, Turecko (Türkiye), 34480
- University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Fatih Bagcıer, MD
- Telefonní číslo: +905442429042
- E-mail: bagcier_42@hotmail.com
-
Istanbul, Turecko (Türkiye), 34668
- University of Health Sciences, Sultan Abdulhamid Han Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Mustafa Hüseyin Temel, MD
- Telefonní číslo: +905342714872
- E-mail: mhuseyintemel@gmail.com
-
Dílčí vyšetřovatel:
- Emre Ata, MD
-
Istanbul, Turecko (Türkiye), 34732
- Erenkoy Physical Therapy and Rehabilitation Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Sefa Kurt, MD
- Telefonní číslo: +905385159528
- E-mail: sefa.kurt@yahoo.com
-
Istanbul, Turecko (Türkiye), 34752
- University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Ozge Gulsum Illeez, MD
- Telefonní číslo: +905326255684
- E-mail: ozgeilleez@gmail.com
-
-
Istanbul
-
Istanbul, Istanbul, Turecko (Türkiye), 34662
- University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Kubra Neslihan Kurt Oktay, MD
- Telefonní číslo: +905352916609
- E-mail: drneslihankurt@gmail.com
-
Dílčí vyšetřovatel:
- Arzu Erbilici, MD
-
Dílčí vyšetřovatel:
- Duygu Geler Kulcu, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Adults aged 18 to 65 years
- Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria
- Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year
- Receiving pregabalin and/or duloxetine treatment for at least 3 months
- Able to live independently in the community
- Literate and able to record symptoms and responses
- No cognitive dysfunction that would interfere with answering study questions
- Able and willing to provide informed consent
Exclusion Criteria:
- Rheumatologic disease
- Renal failure
- Hepatic failure
- Cardiovascular disease
- Hypoglycemia or diabetes mellitus
- Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease)
- Known allergy or hypersensitivity to any active or excipient component of the study syrup
- Use of any other dietary supplement or nutritional support product during the study period
- Pregnancy or lactation
- Active malignancy
- Active infection
- Severe psychiatric disease that may interfere with study participation or assessment
- Refusal to participate or inability to provide informed consent
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Komparátor placeba: Placebo Plus Standard Treatment
Participants will receive matching placebo orally at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine. |
A matching oral placebo syrup without active study ingredients. In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine. The placebo contains deionized water, glycerol, sodium alginate, xanthan gum, steviol glycosides, raspberry flavor, pineapple flavor, strawberry flavor, and mint flavor. |
|
Experimentální: FibroThol Plus Standard Treatment
Participants will receive FibroThol, an oral supplement containing 2-Aticyto Complex and D-ribose, at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine. |
An oral dietary supplement containing 2-Aticyto Complex and D-ribose (marketed as FibroThol). In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Pain Intensity Measured by Numeric Rating Scale (NRS)
Časové okno: Baseline, Week 2, and Week 4
|
Pain intensity will be assessed using the Numeric Rating Scale (NRS), an 11-point scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Neuropathic Pain Measured by DN4
Časové okno: Baseline, Week 2, and Week 4
|
Neuropathic pain symptoms will be assessed using the Douleur Neuropathique 4 (DN4) questionnaire, with a total score range of 0 to 10. Higher scores indicate more neuropathic pain features, and a score of 4 or more suggests neuropathic pain. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Fibromyalgia Impact Questionnaire Score
Časové okno: Baseline, Week 2, and Week 4
|
Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement. |
Baseline, Week 2, and Week 4
|
|
Change in Fibromyalgia Participation Questionnaire Score
Časové okno: Baseline, Week 2, and Week 4
|
Fatigue severity will be assessed using the Fatigue Severity Scale, a 9-item scale with a total score range of 9 to 63. Higher scores indicate greater fatigue severity. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Fatigue Severity Scale (FSS) Score
Časové okno: Baseline, Week 2, and Week 4
|
Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement. |
Baseline, Week 2, and Week 4
|
|
Change in Pittsburgh Sleep Quality Index (PSQI) Score
Časové okno: Baseline, Week 2, and Week 4
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index, with a global score range of 0 to 21. Higher scores indicate poorer sleep quality. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Beck Depression Inventory Score
Časové okno: Baseline, Week 2, and Week 4
|
Depressive symptoms will be assessed using the Beck Depression Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe depressive symptoms. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Beck Anxiety Inventory Score
Časové okno: Baseline, Week 2, and Week 4
|
Anxiety symptoms will be assessed using the Beck Anxiety Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe anxiety symptoms. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Kubra Neslihan Kurt Oktay, MD, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
- Studijní židle: Kubra Nesihan Kurt Oktay, MD, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
Publikace a užitečné odkazy
Obecné publikace
- Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006 Nov;12(9):857-62. doi: 10.1089/acm.2006.12.857.
- Teitelbaum J, Jandrain J, McGrew R. Treatment of Chronic Fatigue Syndrome and Fibromyalgia with D-Ribose- An Open-label, Multicenter Study. The Open Pain Journal. 2012;5:32-37.
- Kerget F, Kerget B, Aksakal A, Kocak AO. Can 2-Aticyto Complex be an Effective Agent for Recovery of The Symptoms and Enhancing Laboratory Parameters in COVID-19 Patients? European Journal of Medical and Health Sciences. 2021;3(2):35-39. doi:10.24018/ejmed.2021.3.2.745.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Neurologické projevy
- Nemoci pohybového aparátu
- Nemoci nervového systému
- Svalová onemocnění
- Duševní poruchy
- Neuromuskulární onemocnění
- Revmatická onemocnění
- Symptomy chování
- Poruchy spánku a bdění
- Poruchy spánku, vnitřní
- Dysomnie
- Patologické stavy, příznaky a symptomy
- Chování
- Příznaky a symptomy
- Bolest
- Úzkostné poruchy
- Fibromyalgie
- Deprese
- Poruchy iniciace a udržování spánku
Další identifikační čísla studie
Další identifikační čísla studie
- HNHAH-KAEK 2025/1
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant data will not be shared. Aggregate results will be reported in publications and trial registry updates.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .